» Articles » PMID: 21177854

The Structure of the Human RNase H2 Complex Defines Key Interaction Interfaces Relevant to Enzyme Function and Human Disease

Overview
Journal J Biol Chem
Specialty Biochemistry
Date 2010 Dec 24
PMID 21177854
Citations 63
Authors
Affiliations
Soon will be listed here.
Abstract

Ribonuclease H2 (RNase H2) is the major nuclear enzyme involved in the degradation of RNA/DNA hybrids and removal of ribonucleotides misincorporated in genomic DNA. Mutations in each of the three RNase H2 subunits have been implicated in a human auto-inflammatory disorder, Aicardi-Goutières Syndrome (AGS). To understand how mutations impact on RNase H2 function we determined the crystal structure of the human heterotrimer. In doing so, we correct several key regions of the previously reported murine RNase H2 atomic model and provide biochemical validation for our structural model. Our results provide new insights into how the subunits are arranged to form an enzymatically active complex. In particular, we establish that the RNASEH2A C terminus is a eukaryotic adaptation for binding the two accessory subunits, with residues within it required for enzymatic activity. This C-terminal extension interacts with the RNASEH2C C terminus and both are necessary to form a stable, enzymatically active heterotrimer. Disease mutations cluster at this interface between all three subunits, destabilizing the complex and/or impairing enzyme activity. Altogether, we locate 25 out of 29 residues mutated in AGS patients, establishing a firm basis for future investigations into disease pathogenesis and function of the RNase H2 enzyme.

Citing Articles

Emerging concepts and treatments in autoinflammatory interferonopathies and monogenic systemic lupus erythematosus.

Goldbach-Mansky R, Alehashemi S, de Jesus A Nat Rev Rheumatol. 2024; 21(1):22-45.

PMID: 39623155 DOI: 10.1038/s41584-024-01184-8.


Structural insight into Okazaki fragment maturation mediated by PCNA-bound FEN1 and RNaseH2.

Tian Y, Li N, Li Q, Gao N EMBO J. 2024; 44(2):484-504.

PMID: 39578540 PMC: 11731006. DOI: 10.1038/s44318-024-00296-x.


De novo variants in immune regulatory genes in Down syndrome regression disorder.

Jafarpour S, Banerjee A, Khoshnood M, Vogel B, Boyd N, Nguyen L J Neurol. 2024; 271(8):5567-5576.

PMID: 38909119 PMC: 11319504. DOI: 10.1007/s00415-024-12521-y.


Distinct features of ribonucleotides within genomic DNA in Aicardi-Goutières syndrome ortholog mutants of .

Kundnani D, Yang T, Gombolay A, Mukherjee K, Newnam G, Meers C iScience. 2024; 27(6):110012.

PMID: 38868188 PMC: 11166700. DOI: 10.1016/j.isci.2024.110012.


Targeting the ribosome to treat multiple myeloma.

Maclachlan K, Gitareja K, Kang J, Cuddihy A, Cao Y, Hein N Mol Ther Oncol. 2024; 32(1):200771.

PMID: 38596309 PMC: 10905045. DOI: 10.1016/j.omton.2024.200771.


References
1.
Rice G, Patrick T, Parmar R, Taylor C, Aeby A, Aicardi J . Clinical and molecular phenotype of Aicardi-Goutieres syndrome. Am J Hum Genet. 2007; 81(4):713-25. PMC: 2227922. DOI: 10.1086/521373. View

2.
Crow Y, Hayward B, Parmar R, Robins P, Leitch A, Ali M . Mutations in the gene encoding the 3'-5' DNA exonuclease TREX1 cause Aicardi-Goutières syndrome at the AGS1 locus. Nat Genet. 2006; 38(8):917-20. DOI: 10.1038/ng1845. View

3.
Frank R . The SPOT-synthesis technique. Synthetic peptide arrays on membrane supports--principles and applications. J Immunol Methods. 2002; 267(1):13-26. DOI: 10.1016/s0022-1759(02)00137-0. View

4.
Eder P, WALDER J . Ribonuclease H from K562 human erythroleukemia cells. Purification, characterization, and substrate specificity. J Biol Chem. 1991; 266(10):6472-9. View

5.
Nettleship J, Brown J, Groves M, Geerlof A . Methods for protein characterization by mass spectrometry, thermal shift (ThermoFluor) assay, and multiangle or static light scattering. Methods Mol Biol. 2008; 426:299-318. DOI: 10.1007/978-1-60327-058-8_19. View